Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

Tu.B.2206 - Tu.B.221 I

Tuesday July 9, 1996

Conclusions: If r 1(N3 ai2b ti catn( nis gop igto bi ercied for chronic C hepatitisin I-f!
patirts, the initial CD+ll 0ounit isin1riipor tnit predoofreinpornse. hoise pa1tint
with a CD4 t-celcouwnt <a0 elc r iiihave iiifcantrate o a riullir cv nx
(p=0.022).[tius, it -cii it thichest{ I n I in e.foi rtin itrare thoe'it ii cirl
stages of HIV irifetioni
Maritiniez F) Iifectnius i ic- tJUnit. Ftnivii it 117 Cliiiical Ic loit. C/ Ramn yii0 ( jrt7.
1'701 I Vitai d. cSpai.t07Ft3 "1.0 Ft Ft20313, Fax: [phone]I
Tu.B.2206
HEPATITIS C INFECTION IN INJECTING DRUG USERS HIV POSITIVE WITH
SEROLOGICAL ATYPICAL PATTERN OF HEPATITIS B
Prerez rri i i"i tt(it in FI. Pr-.Ilo ct irzeo icjar 11in /.1 iir:i yt f
1-ici ci eli y Prierito If jiF iiver slt' II it ii Droiver ty Iof i. 01',-It I
Objective: Tostiidy tleicrpc tit is ovruas (lit V)infect i ii iiinI )t I IIV ~) p tiectl it ntiHK13 as only iii iii ci of I clmit i 13virs ia(F 1BV) iinc ticns.
Methods: iwerity tlireen scrai tc iiiiiIcIDUtentscihai ve bc-citstudind ini the pr escrice of
H17 Vcoinfection switlsFI IV iind itypiicatlpitterniof1KV seirolcicait marikeirs (ily airti I 1c).
Aritibaodies (AK) cioFHCV v-re studiccd by Fl ISA sciei ngrp,(K iLISA, iokit, Spain) and
conrfirmiiatryptents(I rikI117 V III, ii..Jre-tics, telgiuant. P1 [wsndo n by Anpine HCV
techiqcue (Rc cli, Switzer aid).- li nplified product was yciaotylpcd by Ir I p iFICV
(brnyc rieti s, Kiltiuro). F i vei ti iii [[ISA ower c-dcon 1ideter rnriii1-BV (Soiai
iornedica. Italy) iinci1 IV Vs/iII cyrrrr I +12, MurexUSA) scroclooicalrmar kers
Results: All pa tiecitshadci I-V Abshdir i Pt A.liinteen (82.6%)sn-re 11CV/sb positive
and twenty two (95.6~<") wi-ri- F IFV-INA. In fourpatiernts haid hocn detected I16 V KNA
witiot Iit1(-3V Afi CFanty ore warsI Ii V /ib poi-iti vithcout vir oiria.3 hoeriost frecunt genotypo in thio rriplo wIhihcould Libei1pocld118) was 31 (4 I.1 i%) iolloved iiy Ida (33.3%~),
l b (16.6%0.), irid 4lift I I(-,)The-re was onein ~lfectionI la+Ilb.
Conclusions: IiIfn eID U I V (+) plantioii Nitihcoitnieitiin-HBV/HCIV is oer y comntir
thie presenice ioi inti-i1c isolyimariirForfsI11KV iifectuonr. Ini Ilose patients tFhe I CV infectiori is isally vii i-nni lti 9 iiitheyican iii- /1 1negative. In ocii populatior peinctyp3a395
prevalent.
Macurn-A. Pcdcigue uce p.s e ipt,Mic Iobucut 117 Faciity oif Medicine.Plazai Ii toe of intlL~ciK on19yii ii ir n ft tsl - IBV i.Ini iii 1 ii irts
Tu.B.2207
RATE OF SEROCONVERSION TO HEPATITIS B VACCINE INA COHORT OF HIV
INFECTED ADOLESCENTS
Sawyoj iuoy K1,Neshiroii 1S.,'leiri, P t ns, [1iriasan, K.'l 00of, Mcther,.
vPedrati ic/Adolecnt IVF1/AID)S Procir111,-Grady HKinltttSy s-I n id Fri cv> t lnivoirsity
School at Medic in, Ati ii i. P/s. U SA
Background: I IV inerpositiveadoIlesccinto (aes 12 18) whoicntrlcacii-nt (191 institution
receivieIrequirecd iirn nuniv tieo ii norevluactionirfor IHepatitis K vaccine (HBV). 5cr conversion
to HBKV01 17 lao ciirniudhcd ill these youtiIeconr iy to dines r iogressio ion esoured by
CDI4icaunts), viial toaid, oI iii ir i nfti ar oii er. Somue d it r in HIV iinfeted tdiits scig
gest i poeirIrnspoin00 to I IV, [ant tierec is little 1301oratieri in tire I IV ser opooition youth.
Objective: Tol detei rinthin rte of Iliepatuti- KB-ci ocoiivei siori in a coiioirtof 1 Ii-IV
seropositivo youth wtautinglec iiid of(Itti rrnis ioiv.airu oex or Feteocsexci ii).
Methods: iwenity-fve nopF ait ye youtih sotiactiveo liprpmvaccine scinrs br-gan a
seriesef 3 irnriruiiizaitioi cf I11KV withiii 6-ivmivthrs. FCD4lcounts of each youitha vere
deterinead at tie 3rd dose; 1t6/25 youth tin cv u yle to date. Hepatitis K seroclogo deter--
rmined I -4 iv our fir ftei tut-irdii dosen w r irmaird to thic F-334 cociits.
Results:
Patients n=16 CD4 > 500 cells/cmm CD4 200-500 cells/cmm CD4 100-200 Cells/cmm
Sen ilcorisir tcd 1t 1 0
No rlsol-sslil P 2
Dt tiniidicato only 441v of ci 119(9 litiv iyoti isn11d to 11KV, and deccr10107gF U 3counts
correlate itohpotli reip or.
Conclusions:UDci Ivicc inesciiediilno mi lotalwa05 conr elate witih antibody response ini
those seropoasitui youith with FD [31 courts - 500 cells/cria. Protocols will be undertaken
to determ01ne if laryci vaccinec dosnosarid/ovi a 4thdoe ni ry procrcuce miore seoriespoivder s.
Mur yK, Sawyer. MD lou i tis 10Disc--useilProiglii, 341 Pornce do LeoortAve. AtlantaFaeoiria
30f0llotepfio c-'304-h163/86 tosl1t,1I1898 cnmail: F)Vatl01 oroyedu
Tu.B.2208
DUAL AND TRIPLE CHRONIC HEPATIC VIRAL INFECTION IN HIV POSITIVE SUBJECTS: INTERRELATION BETWEEN VIRAEMIA AND EVOLUTION OF LIVER DAMAGE.
Livrera Giancar lo, Do Sai ctis f.M., BK inK mini I.(a., Mar iotta M., FGoldoni F., D't i cr DA.F., Di
Giio A., * ii civ, -- CK a cii c, P.1 iiicci.V Dep of Iftent arid Ti-op FDi - Lniisnrsity "La
Sapierra" Rieu, Italy, ilUniti' di -p toln ycii Htnt Dieci, Iyou

dual on triple hrcviral hepatvitisr,-whnereas 11KV OIlaonvia wao detected in rn ethrir half of
oun cases withv dual HBV/1ID!V or H3BV/FI3CV chronic infectiro110 lIn thise witii trip111e ifectiona
H-DV vii aenia piredomrinarted.Fvoluciton in ciiihboon vas detecein 90/-II38. espeniarhoy irrong
AIDS cines (6/8 eAIDS) cad,-etr.Ith0 Iongipr nunrItion of irfto1n11(rnc- nir ccAllDS031 y vonrsus nrcan lye nirrirAiDt 30 y::).
Frr na Gianic tIrlr. pt tInitrtcusnritd lropcaIFDiseaises, La Saipienz ni ii city, Policlirnico
Unrberto I Vile de!i Fci ti 155, 00161 Royr-, IralyTnl. 30 6 -i-156 38i1 Iix:-39 6 -10589 19
Tu.B.2209
ALPHA-INTERFERON FOR CHRONIC HEPATITIS C IN HIVINFECTED PATIENTS:
RESPONSE TO TREATMENT AND RELAPSES
Bravo Kosa, Sovia o V. (arcri-S inn iv rirlici (It usA. C u isi I,/-r, itF, I~iar IiPF NSL iF
I PFATMLI: IAND FlL/ri1SFS IViule dcl licidnce IS55,(00161 R3me, i Il-. l.39 6
4456388 Fax: [phone] I19
air age non AIDS 30 y I
Introduction: Liven duis-ase secondary to D( I irnfection is.a riosig caruse rf rvurriidity and
mvor tality urnongst DIV -I irduvidualsmainly tu those ifcted parnrtor illy suchiiasijectiung
drug users, hemophiliacs and tirinsfusedl patients.VWe iralzend thre sirntI ad Iany-tc-rmiv
response-. to.alphar-IFN thverapy i0 HIV + patierts mnthfmhrnic hopalitis FC.
Methods: I1I9 Ipatents withv C fIC (90 HIV -+ with F Dl >- 200/mro3 anad 29 F IIV rey) wonre
included i aeunltcentre, proipective, openr, ron-randornuced, obserationaltstudy FN wan
given un a dosage of 5 rvegU sc t1w durngn 3 rnontirs. folloswed it tivose wiuorospoinded by
3 naegaD sc tim ann acituonali 9 months. In both DIV a-aaid HIV-roy irdividuaito, response
rates obtainod early (at 3 monuths of beginnngripN)..at theve nun cf ti notrnrirt (I!? mnths)
anad 18 mronths liter were then comnpared.
Results: Biochremical results (ALT nor ni itouatucai) fror 1(07 I itiurnit wino sirmpted the
studyareisownu in lire tuble.

EARLY RESPONSE
LATE RESPONSE
SUSTAINED RESPONSE

HIV-pos (nii 80) HIV-neg (n=-27) p
38.8% 43. Dr 0.602
32.5% 37.0% 0.666
22.5 '2591() 0.7i6

Globilly, scrunovHCV-PNA conrrelated withr ALF v/non,,irid PCR ~+Ircsuits firequently areceded Al I enhincoenvnt in relapses. FHowever. PCR + 10epon-cod in two subiects (one DIV
~ and anothuer IVIuceg) uter inding ryetntmnnunt despiteropeateri rormnoa ALT dcinrg 18
mnonths of follow-up. COiitire oliheu hvnid, twia othverpatienrviseioc ALT ciespite r epeatod
negative HdCV PCR results. Given that Ifhicontwvo patientvs wore for nr- i (3Is, undercariiage
of Hepatitis C virus infection iin them could explainn this findurgy
Conclusion: Pesponvse. ratcsto IFN arid elapses Oemrs to bfir-eun-- imilin Ii13V rie nid
DIV pos nduvid~uals south ild urnnunoscippresson.
Dr K. Bruvo. Servuce Infectionu- Dineaes i1SF-III, CJPRufunl ( lvo 7,2" A. 2801tO-Madrid. Spain.
Phrore: (34- I) a3110807. Fax: [phone]
Tu.B.22 10
RELATIONSHIP BETWEEN IMMUNE STATUS AND HISTOLOGICAL COURSE OF
HEPATITIS C IN HIV INFECTED PATIENTS
Roger PereMaruor, St Pacul MC**, Puglese P*, Fuzbnt (G*" *, Monvdain VP Mchiels fa*,
Deilamoouca P*. * infectious Diseanss pt: *v*Pathvology Dpt: ** *Intc-i noit Medicire opt
Unuversity Hospital. Nice, Firance.
Objective: To determine thre influence of imvmune- status cci tire histoIouicait les ioscut the
liver observed during hvepatitun C in DIV infcted pitients.
Methods: A retroupective study of I-IIVnfctc-d patients in whromv a liven biopsy (LB) was
perfornmed for chrconic hepatitis C or loing tenri pyr coma investugatuona. IHepatitus C Viirus
(IICV) status was determnrined by second generion (LISA tenting. Dita woro reviewed
frora pationtn' charts. Non of time patients loud received acknowledgod eifective theraupy for
hepatitis C prior to LB. Presumed date of H3CV corntamna tiono mis th it of irst exposcure to
a risk. fatoc.
Results: The population consisted oh SO patients (74% nmale) witty ronoan age 33 ~ 9 yin:
DIV contamvination was throuyh IV drug usc ini 78.0 of cases Dua tioriooIVHICcanruiage wan
8.4 ~ 2 yin [range: 5- I3]. Thirty one paleto (62%) wore at stauge C3 acccrcdung to CDC
classifcationu. lean CD4 lynmphocyte counvtmis 213 -~ 328/mm (u[rangn: I -1700], mvean
CU8 lynmphnccyte couant was 500 +1 382/nu3 [rangye: 35-15003]. 1Hstoogucal exanminiton
revealod cirrhuosis no 7 cases (I -4%), chrronvic activo hepatitis ini 19 ca100 (39vt, lout-specufic
lobular hepatitis iii 17 cases, LB man normnal i 7 patienots. Ptresenuceofo chronic atis-e hepatitis was associated with highest CDI and CDB lymvphocyte cocunt conmparod to non -progressive hepatitis: CD4 396 ~ 435 vs 104 ~tI 65/now3 (p=0,01I8). and CD8I 75-3 + 423 vs
342 ~ 260/nr3 (p<010-3) respectively Presenace of cr dris or chronic activc- hepatitis onas
not correlated to duration oh viral hepatutis C disease.
Conclusions: Histological lesions of thiveruoi orvand dcingythe 109oaurIofrnepatitis C
amaong IHIVinfected patients depend ona ptienat rrruturve stitus, ard arcenmore sevnre when
CD4 anti CD8 lymphocyte nub-population counrts ace not deeply depresned.
PM RUGER, Senrvice de Maladies Infectuouses FlOptal IAn chet KP79. 06202 Nice codex 03.
France Telephnone: 00 33 92 03 54 67 Fax: [phone]
Tu.B.2211 I
TRYPANOSOMA CRUIZI ENCEPHALITIS (CHAGAS' DISEASE) IN A PATIENT WITH
HIV INFECTION.
Cenuotto Maiana ', Zala C 13, BandariS2, Schijmaiv A2. Kevin M2,IsoaiFDU1, Gonvzalez
Cappa SM. Department of Micirobiology, Faculty of Medicine, Unmver sity of Buenos Airen I:;
INGEBI-CDNICET Buenos Aires, Argentina2: Canaudi an I-]IV Trials Network. Vncouver,
Canada9
Introduction: Chagas' disease remains enrdeic in Latin Anuericuaon-fyre.110(10x11ately 1.3
mllion people are infected with the Hunuan Imvmunodeiciency Viirus (H-IV). Althuoughr
Chagas' disesse ban been recognuzed n the context ofHDIV ifectiorn. t haus rarely beono
micro-buologicilly provena. Hence. the clunical spectr urn of Cluagass dsoase uni dually irfcted
indivuduals s ivot fully establusbed.
Objective-To report the development of Chagis' disease prosentrog us hr aun moarotlesuon

P(
HBV/HDVI
(S/B <rrniosi I 1FF,
HBV/HCV t
(4/tO 0cirrhtosis) (66,
HBV/HDV/HCV '1/
(I 1/20 ciii bonus) (af
Conclusions: In 3holyof I

HBVDNA HDVRNA HCVRNA
os. Neg. Pos. Neg. Pos. Neg.
6 2/6 0-l II 06 6/6
- ( 33~f (~lls100%)
19 3/9 / / 1/7 6/7

i)
10V rip

(33.3 -i I 10

(11.30sf (85.7%)
5/13 8/13 3/Il It/I4
(38.5%) (61,Si) (11,4) (78.6%)
curt Ic- ithveslt rio iity of FHIV S cases muti

301